Profile
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 4 (2019), Article ID 4:IJCPP-145, 5 pages
https://doi.org/10.15344/2456-3501/2019/145
Research Article
Pharmacotherapy Follow-up to Pediatric Patients with Inflammatory Bowel Disease

Javiera Bucarey-Vivanco1, Josefa Chávez-Esparza1, Andrea Campos-Loyola2 and Elena MaríaVega*1

1Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile. Sergio Livingstone, Independencia, Santiago, Chile
2Servicio de Farmacia, Hospital Exequiel González Cortés, Gran Avenida José Miguel Carrera, San Miguel, Región Metropolitana, Chile
Dr. Elena María Vega, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile. Sergio Livingstone P. 1007, Of. 212, Independencia, Santiago 8380492, Chile; E-mail: emvega@ciq.uchile.cl
13 July 2019; 03 December 2019; 05 December 2019
Bucarey-Vivanco J, Chávez-Esparza J, Campos-Loyola A, MaríaVega E (2019) Pharmacotherapy Follow-up to Pediatric Patients with Inflammatory Bowel Disease. Int J Clin Pharmacol Pharmacother 4: 145.doi: https://doi.org/10.15344/2456-3501/2019/145

References

  1. Rosen MJ, Dhawan A, Saeed SA (2015) Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr 169: 1053-1060. View
  2. Egberg MD, Kappelman MD, Gulati AS (2018) Improving Care in Pediatric Inflammatory Bowel Disease. Gastroenterol Clin North Am 47: 909-919. View
  3. Zhang YZ, Li YY (2014) Inflammatory bowel disease: Pathogenesis. World J Gastroenterol 20: 91-99. View
  4. Meligrana NE, Quera R, Figueroa C, Ibáñez P, Lubascher J, et al. (2019) Factores ambientales en el desarrollo y evolución de la enfermedad inflamatoria intestinal. Rev Med Chile 147: 212-220. View
  5. Simian D, Fluxá D, Flores L, Lubascher J, Ibáñez P, et al. (2016) Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol 22: 5267-5275. View
  6. Tiao DK, Chan W, Jeganathan J, Chan JT, Perry J, et al. (2017) Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis 23: 1257-1261. View
  7. Gomollón F (2016) Treatment adherence is always worse than we think: an unresolved problem in inflammatory bowel disease. Gastroenterol Hepatol 1: 14-19. View
  8. Mohammed MA, Moles RJ, Chen TF (2016) Impact of Pharmaceutical Care Interventions on Health-Related Quality-of-Life Outcomes. Ann Pharmacother 50: 862-881. View
  9. Correia JPR, Costa ACD, Rocha EA, Quidute ARP, Cândido DDS, et al. (2017) Pharmacotherapeutic follow-up of patients with Chagas disease using in use of benznidazole. Rev Soc Bras Med Trop 50: 334-340. View
  10. Silva ACS, Sousa DSC, Perraud EBC, Oliveira FRA, Martins BCC, et al. (2018) Pharmacotherapeutic follow-up in a respiratory intensive care unit: description and analysis of results. Einstein (Sao Paulo) 16: eAO4112. View
  11. Heredia-Balladares E, Barreno-Heredia A, Martínez-Martínez F (2017) Guía de actuación para el farmacéutico comunitario en enfermedad inflamatoria intestinal. Ars Pharmaceutica 58: 115-126. View
  12. Dotson JL, Crandall WV, Zhang P, Forrest CB, Bailey LC, et al. (2015) Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice. J Pediatr Gastroenterol Nutr 60: 200-204. View
  13. Kalichman SC, Amaral CM, Swetzes C, Jones M, Macy R, et al. (2001) A simple single-item rating scale to measure medication adherence: further evidence for convergent validity. J Int Assoc Physicians AIDS Care (Chic) 8: 367-374. View
  14. Ortega-Suárez FJ, Sánchez-Plumed J, Pérez-Valentín MA, Pereira-Palomo P, Muñoz-Cepeda MA, et al. (2011) Validation on the simplified medication adherence questionnaire (SMAQ) in renal transplant patients on tacrolimus. Nefrologia 31: 690-696. View
  15. Cipolle RJ, Strand L, Morley P (2012) Pharmaceutical Care Practice. (3rd edition), New York: Mc Graw Hill Medical, USA, 697 p.
  16. Carrillo-González GM, Sánchez-Herrera B, Barrera-Ortiz L (2014) Caring ability of family caregivers of children and adults with chronic illness. Index Enferm 23: 129-133. View
  17. Vaquiro-Rodríguez S, Stiepovich-Bertoni, J (2010) Informal care, a challenge assumed by women. Cienc Enferm 16: 17-24. View
  18. Fairfax A, Brehaut J, Colman I, Sikora L, Kazakova A, et al. (2019) A systematic review of the association between coping strategies and quality of life among caregivers of children with chronic illness and/or disability. BMC Pediatr 19: 215. View
  19. de Carpi JM (2007) Enfermedad Inflamatoria Intestinal Pediátrica. Bol Pediatr Arag Rioj Sor 37: 78-81.
  20. Medina-Benítez E, Prieto-Bozano G, Rodríguez-Reynoso M, Suárez-Cortina L: Enfermedad inflamatoria intestinal. View
  21. Zheng X, Zhang Z, Wang B, Li J, Qiu C, et al. (2019) Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 98: e15113. View
  22. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, et al. (2018) Management of Paediatric Ulcerative Colitis, Part 1 : Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 67: 257-291. View
  23. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, et al. (2017) Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis 11: 769- 784. View
  24. Jüngst C, Gräber S, Simons S, Wedemeyer H, Lammert F, et al. (2019) Medication adherence among patients with chronic diseases: a surveybased study in pharmacies. QJM. 112: 505-512. View
  25. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353: 487-497. View
  26. Ham M, Moss AC (2012) Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol 5: 113-123. View
  27. Arrabal-Durán P, Durán-García ME, Ribed-Sánchez A, Hidalgo-Collazos P, Sanjurjo-Sáez M, et al. (2014) Pharmaceutical interventions in prescriptions for patients admitted with chronic renal failure. Nefrología 34: 710-715. View
  28. Pan American Health Organization (2013) Servicios farmacéuticos basados en la atención primaria de salud. Documento de posición de la OPS/OMS. Washington, DC: OPS, 106p. View